Geneva, Aug. 29 -- International Clinical Trials Registry received information related to the study (JPRN-jRCT2011250026) titled 'Phase 2 Trial of 177Lu-PSMA-I&T in Patients with PSMA-Positive Metastatic Castration-Resistant Prostate Cancer' on Aug. 8.
Study Type: Interventional
Study Design:
single arm study, open(masking not used), uncontrolled control, single assignment, treatment purpose
Primary Sponsor: Masuda Ryohei
Condition:
Prostate Cancer
Intervention:
To confirm PSMA positivity, a single intravenous dose 296 MBq (+-10 percent) of R-241B is administered, followed by a PET/CT scan. Those who test positive will receive 7.4 GBq (+-10 percent) of R-242C intravenously every 6 weeks for 6 cycles while being maintained at castr...